Here, we developed a GEMM of metastatic TNBC driven by Prune-1 (MMTV–Prune-1/Wnt1) as a useful resource for preclinical studies to determine the efficacy of immunotherapeutic agents for treatment of established metastatic disease. Here, WNT1 is linked to metastatic neoplasm.